Literature DB >> 11834629

Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart.

Hugh Clements-Jewery1, David J Hearse, Michael J Curtis.   

Abstract

Ventricular fibrillation (VF) in conscious rats with coronary artery ligation occurs in two phases, before (phase 1) and after (phase 2) 90 min of ischaemia respectively. The mechanisms of phase 2 VF are not established. Interestingly, phase 2 VF is absent in isolated (denervated) buffer-perfused rat hearts. We investigated whether catecholamine supplementation (to mimic sympathetic drive) was sufficient to restore phase 2 VF in such hearts. Isolated rat hearts (n=10 per group) underwent coronary ligation for 240 min. At 90 min, during a period of relative electrical stability, the perfusion solution was switched from standard (Krebs) to identical solution or Krebs containing catecholamines (313 nM noradrenaline and 75 nM adrenaline) with or without 10 microM trimazosin (an alpha(1)-adrenoceptor antagonist) or 10 microM atenolol (a beta(1)-adrenoceptor antagonist). Although in all groups the incidence of phase 1 VF was high (80 - 100%), the temporal distribution of VF was monophasic, i.e. only one heart in one group developed phase 2 VF (P=NS). Other ventricular arrhythmias (e.g., tachycardia; VT) exhibited a similar temporal distribution. Nevertheless, haemodynamic changes confirmed sympathomimetic effects of catecholamines, e.g., heart rate was increased from 278+/-7 beats min(-1) in controls to 335+/-8 beats min(-1) (P<0.05) by catecholamines, an effect that could be blocked by atenolol (285+/-7 beats min(-1)) but not by trimazosin (342+/-12 beats min(-1)). Coronary flow was correspondingly increased from 7.7+/-0.7 ml min(-1) g(-1) to 16.5+/-1.3 ml min(-1) g(-1) (P<0.05); this effect could be blocked by atenolol (8.1+/-0.6 ml min(-1) g(-1)) and was enhanced by trimazosin (20.7+/-2.4 ml min(-1) g(-1)). In conclusion, despite evidence of adequate alpha- and beta-adrenoceptor activation, catecholamine supplementation to isolated buffer-perfused rat hearts was insufficient to restore phase 2 VF. It therefore appears unlikely that catecholamines alone mediate phase 2 VF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834629      PMCID: PMC1573173          DOI: 10.1038/sj.bjp.0704509

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Mechanisms for the positive inotropic effect of alpha 1-adrenoceptor stimulation in rat cardiac myocytes.

Authors:  D Fedida; R A Bouchard
Journal:  Circ Res       Date:  1992-09       Impact factor: 17.367

2.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

Authors:  A L Waldo; A J Camm; H deRuyter; P L Friedman; D J MacNeil; J F Pauls; B Pitt; C M Pratt; P J Schwartz; E P Veltri
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

Review 3.  Endogenous myocardial protective (antiarrhythmic) substances.

Authors:  J Parratt
Journal:  Cardiovasc Res       Date:  1993-05       Impact factor: 10.787

Review 4.  Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias?

Authors:  S Rees; M J Curtis
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

5.  Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia.

Authors:  S A Rees; M J Curtis
Journal:  J Cardiovasc Pharmacol       Date:  1995-08       Impact factor: 3.105

6.  Anion manipulation, a novel antiarrhythmic approach: mechanism of action.

Authors:  M J Curtis; P B Garlick; P D Ridley
Journal:  J Mol Cell Cardiol       Date:  1993-04       Impact factor: 5.000

7.  Brief, intermediate and prolonged ischemia in the isolated crystalloid perfused rat heart: relationship between susceptibility to arrhythmias and degree of ultrastructural injury.

Authors:  T Ravingerova; N Tribulova; J Slezak; M J Curtis
Journal:  J Mol Cell Cardiol       Date:  1995-09       Impact factor: 5.000

Review 8.  Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease.

Authors:  M J Curtis; M K Pugsley; M J Walker
Journal:  Cardiovasc Res       Date:  1993-05       Impact factor: 10.787

9.  Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats.

Authors:  C F Opitz; G F Mitchell; M A Pfeffer; J M Pfeffer
Journal:  Circulation       Date:  1995-07-15       Impact factor: 29.690

10.  One hour of myocardial ischemia in conscious dogs increases beta-adrenergic receptors, but decreases adenylate cyclase activity.

Authors:  D E Vatner; D R Knight; Y T Shen; J X Thomas; C J Homcy; S F Vatner
Journal:  J Mol Cell Cardiol       Date:  1988-01       Impact factor: 5.000

View more
  12 in total

1.  Unravelling mechanisms underlying ischaemic arrhythmias - the importance of models.

Authors:  L J Guppy; M J A Walker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.

Authors:  Hugh Clements-Jewery; Gajen Sunthar Kanaganayagam; Ruchi Kabra; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  Contractile function assessment by intraventricular balloon alters the ability of regional ischaemia to evoke ventricular fibrillation.

Authors:  Catherine D E Wilder; Radwa Masoud; Duygu Yazar; Brett A O'Brien; Thomas R Eykyn; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2015-12-04       Impact factor: 8.739

4.  The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 5.  Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

6.  Intracoronary infusion of catecholamines causes focal arrhythmias in pigs.

Authors:  Harish Doppalapudi; Qi Jin; Derek J Dosdall; Hao Qin; Gregory P Walcott; Cheryl R Killingsworth; William M Smith; Raymond E Ideker; Jian Huang
Journal:  J Cardiovasc Electrophysiol       Date:  2008-05-09

7.  Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.

Authors:  Kathryn E Baker; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

8.  Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.

Authors:  Hugh Clements-Jewery; Ellen Andrag; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

9.  Facilitation of ischaemia-induced ventricular fibrillation by catecholamines is mediated by β1 and β2 agonism in the rat heart in vitro.

Authors:  Catherine D E Wilder; Nikoleta Pavlaki; Tutku Dursun; Paul Gyimah; Ellice Caldwell-Dunn; Antonella Ranieri; Hannah R Lewis; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

10.  The persistent sodium current blocker riluzole is antiarrhythmic and anti-ischaemic in a pig model of acute myocardial infarction.

Authors:  Steven M Weiss; David A Saint
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.